StockData
Rigel Pharmaceuticals Inc logo

Rigel Pharmaceuticals Inc (RIGL) stock

RIGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 11/30
$42.92−0.81 (-1.85%)

Close on Nov 17, 2026Market cap $801.74MP/E 2.7Yield –

Rigel Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Rigel Pharmaceuticals's operating cash flow for the twelve months ending Jun 30, 2026 was $79.39M, up 20.6% year over year. For fiscal 2025 it was $75.66M, up 140.4% from the year before. The highest annual figure on record is $75.66M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$75.66M+140.4%
FY2024Dec 31, 2024$31.47M–
FY2023Dec 31, 2023-$5.74M–
FY2022Dec 31, 2022-$73.76M-1354.8%
FY2021Dec 31, 2021$5.88M–
FY2020Dec 31, 2020-$52.19M–
FY2019Dec 31, 2019-$41.51M–
FY2018Dec 31, 2018-$58.83M–
FY2017Dec 31, 2017-$77.56M–
FY2016Dec 31, 2016-$75.89M–
FY2015Dec 31, 2015-$23.41M–
FY2014Dec 31, 2014-$69.75M–
FY2013Dec 31, 2013-$86.08M–
FY2012Dec 31, 2012-$85.21M–
FY2011Dec 31, 2011-$69.38M-248.4%
FY2010Dec 31, 2010$46.74M–
FY2009Dec 31, 2009-$102.78M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$30.65M+0.4%
Q1 FY2026Mar 31, 2026$2.73M–
Q4 FY2025Dec 31, 2025$21.98M+51.6%
Q3 FY2025Sep 30, 2025$24.03M+10.8%
Q2 FY2025Jun 30, 2025$30.54M+10011.6%
Q1 FY2025Mar 31, 2025-$893.00K–
Q4 FY2024Dec 31, 2024$14.50M–
Q3 FY2024Sep 30, 2024$21.68M–
Q2 FY2024Jun 30, 2024$302.00K-94.9%
Q1 FY2024Mar 31, 2024-$5.01M–
Q4 FY2023Dec 31, 2023-$6.24M–
Q3 FY2023Sep 30, 2023-$1.36M–
Q2 FY2023Jun 30, 2023$5.93M–
Q1 FY2023Mar 31, 2023-$4.07M–
Q4 FY2022Dec 31, 2022-$21.91M–
Q3 FY2022Sep 30, 2022-$13.30M–
Q2 FY2022Jun 30, 2022-$12.91M-123.4%
Q1 FY2022Mar 31, 2022-$25.64M–
Q4 FY2021Dec 31, 2021-$19.09M–
Q3 FY2021Sep 30, 2021-$10.30M–
Q2 FY2021Jun 30, 2021$55.22M–
Q1 FY2021Mar 31, 2021-$19.96M–
Q4 FY2020Dec 31, 2020-$15.57M–
Q3 FY2020Sep 30, 2020-$19.48M–
Q2 FY2020Jun 30, 2020-$14.04M–
Q1 FY2020Mar 31, 2020-$3.09M–
Q4 FY2019Dec 31, 2019-$9.65M-182.9%
Q3 FY2019Sep 30, 2019-$14.64M–
Q2 FY2019Jun 30, 2019-$16.65M–
Q1 FY2019Mar 31, 2019-$569.00K–
Q4 FY2018Dec 31, 2018$11.64M–
Q3 FY2018Sep 30, 2018-$20.08M–
Q2 FY2018Jun 30, 2018-$26.99M–
Q1 FY2018Mar 31, 2018-$23.39M–
Q4 FY2017Dec 31, 2017-$19.72M–
Q3 FY2017Sep 30, 2017-$17.61M–
Q2 FY2017Jun 30, 2017-$19.47M–
Q1 FY2017Mar 31, 2017-$20.76M–
Q4 FY2016Dec 31, 2016-$12.46M–
Q3 FY2016Sep 30, 2016-$22.57M–

More Rigel Pharmaceuticals figures

See a number that looks wrong?